Strategy suggests combining surrogate markers for kidney disease progression in clinical trials

kidney

Change in urinary albumin:creatinine ratio (UACR) and glomerular filtration rate (GFR) slope are markers that are individually used as surrogates of chronic kidney disease progression in clinical trials. Investigators recently developed a strategy that combines information from the treatment effects on the two to improve the prediction of treatments’ effects on patient outcomes. Their research will be presented at ASN Kidney Week 2022 November 3–November 6.

The scientists used data from 41 randomized controlled trials of chronic kidney disease progression to develop their strategy and then applied the results to the design of a phase 2 trial to assess design implications (such as sample size and follow-up time) for using UACR change and GFR slope individually or in combination.

The analysis revealed that in phase 2 clinical trials with sample sizes of 100–200 patients per arm or follow-up times ranging between 1 and 2 years, combining UACR change and GFR slope improves predictions of treatments’ effects on clinical endpoints.

Source: Read Full Article

Related posts:
  1. 10 symptoms acid reflux
  2. Parents of terminated foetus 'had no hope after test'
  3. Novel mechanical mechanism of metastatic cancer cells in substrates of different stiffness revealed
  4. Broomfield returning to Level Yellow on Colorado’s COVID-19 dial
  5. EXPLAINER: What does it mean for COVID-19 to be endemic?